乳腺癌CYP2D6、SULT1A1基因多态性与他莫昔芬疗效的关系

Relationship between CYP2D6,and SULT1A1 gene polymorphisms and treatment effect of tamoxifen

目的探讨乳腺癌患者CYP2D6、SULT1A1基因多态性与他莫昔芬疗效相关性。方法2018年1月至2019年1月接受他莫昔芬治疗的乳腺癌患者,检测CYP2D6(100C>T)、SULT1A1638(G>A)基因型,分析其与临床病理参数、生存的关系;Kaplan-meier生存分析,Log-rank检验生存差异。结果入组203例患者,CYP2D6(100C>T)CC、CT、TT分别44例(21.67%)、117例(57.64%)、42例(20.69%)。SULT1A1638(G>A)均为GG型,无GA或AA型。CC及CT型患者2年总生存率高于TT型(P=0.013)。CC及CT型患者OS较TT型患者延长(P=0.001)。结论CYP2D6(100C>T)TT型他莫昔芬治疗后总生存较CC、CT型明显下降。SULT1A1638(G>A)未发现等位基因突变。

Objective To investigate the correlation between CYP2D6,and SULT1A1 gene polymorphisms and treatment effect of tamoxifen(TAM)in patients with breast cancer.Methods From January 2018 to January 2019,203 patients treated with TAM were included in the study.The genotype of CYP2D6(100C>t)and SULT1A1638(G>A)was detected,and the correlation between genotypes,clinicopathological parameters,and the prognosis was analyzed.Kaplan Meier method was used for survival analysis,and log rank test was used to test whether there was survival difference among patients.Results Among 203 cases,44 cases(21.67%),117 cases(57.64%)and 42 cases(20.69%)were CYP2D6(100C>t)CC,CT and TT respectively.Sult1A1638(G>A)was all GG type,and no GA or AA type was found.The 2-year OS rate of patients with CC and CT was higher than that of patients with TT(P=0.001).The OS of CC and CT patients was significantly longer than that of TT patients(P=0.001).Conclusion The OS of TT patients after TAM treatment is significantly lower than that of CC and CT patients.No allele mutation is found in SULT1A1638(G>A).